Cardiovascular Endocrinology and Metabolism Volume 7 Issue 1

LitStream

Journal Article

Cardiovascular Endocrinology & Metabolism

Krentz, Andrew J.

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000149 pmid:31646269

LitStream

Journal Article

Cardioprotective glucose-lowering medications: evidence and uncertainties in a new therapeutic era

Krentz, Andrew J.; Chilton, Robert

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000150 pmid:31646270

LitStream

Journal Article

Pathophysiology of cardiovascular disease in diabetes mellitus

Rodriguez-Araujo, Gerardo; Nakagami, Hironori

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000141 pmid:31646271

Diabetes mellitus elicits cellular, epigenetic, and post-translational changes that directly or indirectly affect the biology of the vasculature and other metabolic systems resulting in the apparition of cardiovascular disease. In this review, we provide a current perspective on the most recent...

LitStream

Journal Article

Heart failure: an underestimated therapeutic target in diabetes

Marx, Nikolaus

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000138 pmid:31646272

Heart failure (HF) is a frequent finding in patients with diabetes and is associated with an impaired prognosis with respect to the need for hospitalization as well as mortality. The following article presents an overview of the incidence and prognosis of HF in patients with type 2 diabetes and...

LitStream

Journal Article

The impact of glucose-lowering medications on cardiovascular disease

Avogaro, Angelo; De Kreutzenberg, Saula Vigili; Fadini, Gian Paolo

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000139 pmid:31646273

Patients with type 2 diabetes mellitus die most frequently from cardiovascular disease. Metabolic control is mandatory both for preventing long-term complications and for reducing the negative effects of the exposure of the other risk factors. In this article, we will describe the most commonly...

LitStream

Journal Article

Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists

Reed, Josh; Kanamarlapudi, Venkateswarlu; Bain, Stephen

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000147 pmid:31646274

Glucagon-like peptide 1 (GLP-1)-based therapies reduce hyperglycaemia in type 2 diabetes. Diabetes cardiovascular comorbidity remains prevalent, although current treatments are effective at reducing hyperglycaemia. GLP-1 exerts specific actions on the cardiovascular system in both healthy...

LitStream

Journal Article

Integrating cardioprotective glucose-lowering medications into clinical practice

Mudaliar, Sunder

2018 Cardiovascular Endocrinology & Metabolism

doi:10.1097/XCE.0000000000000142 pmid:31646275

Patients with type 2 diabetes suffer from both microvascular and macrovascular complications. Optimal glycemic control is well known to reduce the microvascular complications of retinopathy, nephropathy, and neuropathy. However, despite having multiple classes of antidiabetes medications, we have...

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cardiovascular Endocrinology and Metabolism Volume 7 Issue 1

Related Journals:

Advanced Search

Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cardiovascular Endocrinology and Metabolism Volume 7 Issue 1

Related Journals:

Our policy towards the use of cookies